The comprehensive new drugs screening and evaluation center was launched in July of 2014. The goal of our center is to set up different platforms to carry out high-throughput and high-content screening of drug compounds that can be developed for clinical use to fight the most threatening diseases such as cancer, cardiovascular diseases, diabetes, etc. We are currently adoptingmodern pharmacology, molecular biology, cell biology, bioinformatics and other multi-disciplined technologies, combined with modern instruments such as OperettaTM bench-top high content screening system, PlexeraPlexArray™ high-content screening system to identify drug targets, study the mechanisms of drug action and screen marine chemical and natural compounds for drug discovery. We also evaluate the drug safety by ADMET and pharmcodynamics using small animal models.
The major direction of our center is to establish model systems including cellular and animal models to carry out phenotypic and targets-directed drug screenings, assess drug activity, and evaluate drug safety. The other direction in our center is to identify drug targets by studying the mechanisms underlying the pathogenesis of diseases such as cancer. We also provide professional consultation for designing drug screening strategies according to customers' demands.
Our center provide technical services for establishing the high-throughput and high-content screening models, carrying out drug screening and evaluating drug efficacy and safety. We can also provide services for different cell lines (normal, cancer, and genetically modified cell lines), SPF laboratory small animal products and related services. We can provide documentation services for new drug application and patent application.Our center warmly welcome colleagues from different institutions and enterprises to collaborate on the projects with common interests.
